CD8A and neoplasm: However, targeting programmed death-1 (PD1)-amplified activation of intra-tumor CD8+PD1+ T cells did not result in tumor regression, thereby suggesting tumor immune surveillance was damaged and possibly because of the aberrant NASH-induced T cell activation (119).